Healthcare Industry News: NitroMed
News Release - October 29, 2007
N30 Pharma Announces License Agreement With NitroMed, Inc.
BOULDER, Colo., Oct. 29 (HSMN NewsFeed) - N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of respiratory drugs that target endogenous s-nitrosothiols, today announced a licensing agreement with NitroMed Inc. (Nasdaq: NTMD ) covering the respiratory use of a s-nitrosothiol drug candidate. Financial terms of the deal were not disclosed."I am extremely pleased to announce this agreement. NitroMed is a leader in exploring the medical utility of Nitric Oxide and s-nitrosothiol therapies, and has foundational intellectual property in the area," commented Charles Scoggin, M.D., Chairman of N30 Pharma.
N30 Pharma is developing s-nitrosothiol therapies for critical unmet needs in important respiratory diseases such as cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD). S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone, as well as having other effects. N30 is a privately held company headquartered in Boulder, Colorado.
Source: N30 Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
